The fight against drug-resistant germs in hospitals is a major focus of the start-up biotech company Curetis. The firm, founded in 2007, has developed a diagnostic system to locate bacterial infections more quickly, identify them more precisely identified and, as a result, treat them more effectively.
This year Curetis faces another type of resistance: The wariness German investors feel for the biotech industry.
Curetis, based near Stuttgart, plans an initial public offering in the fourth quarter to bring in fresh capital in the mid-double digit millions range. The money is primarily earmarked for a planned expansion in the U.S. market and development of its own sales force in North America.